- Home
- PAR vs CNTA Comparison
PAR vs CNTA Comparison
Compare PAR & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAR
- CNTA
- Stock Information
- Founded
- PAR 1968
- CNTA 2020
- Country
- PAR United States
- CNTA United Kingdom
- Employees
- PAR N/A
- CNTA N/A
- Industry
- PAR Office Equipment/Supplies/Services
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- PAR Miscellaneous
- CNTA Health Care
- Exchange
- PAR Nasdaq
- CNTA Nasdaq
- Market Cap
- PAR 2.7B
- CNTA 1.6B
- IPO Year
- PAR N/A
- CNTA 2021
- Fundamental
- Price
- PAR $69.06
- CNTA $14.29
- Analyst Decision
- PAR Strong Buy
- CNTA Strong Buy
- Analyst Count
- PAR 7
- CNTA 10
- Target Price
- PAR $79.86
- CNTA $28.78
- AVG Volume (30 Days)
- PAR 431.1K
- CNTA 980.2K
- Earning Date
- PAR 08-07-2025
- CNTA 08-12-2025
- Dividend Yield
- PAR N/A
- CNTA N/A
- EPS Growth
- PAR N/A
- CNTA N/A
- EPS
- PAR N/A
- CNTA N/A
- Revenue
- PAR $383,768,000.00
- CNTA $15,000,000.00
- Revenue This Year
- PAR $30.06
- CNTA N/A
- Revenue Next Year
- PAR $16.97
- CNTA N/A
- P/E Ratio
- PAR N/A
- CNTA N/A
- Revenue Growth
- PAR 37.95
- CNTA 118.88
- 52 Week Low
- PAR $43.50
- CNTA $9.00
- 52 Week High
- PAR $82.24
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- PAR 58.95
- CNTA 61.38
- Support Level
- PAR $65.57
- CNTA $13.22
- Resistance Level
- PAR $70.89
- CNTA $14.74
- Average True Range (ATR)
- PAR 1.98
- CNTA 0.73
- MACD
- PAR 0.23
- CNTA 0.14
- Stochastic Oscillator
- PAR 79.49
- CNTA 85.11
About PAR PAR Technology Corporation
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.